ALDX on Nasdaq
Aldeyra Therapeutics, Inc.
$0.76 down 0.03 (3.67%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.9
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $25.7M | $48.2M |
| General and administrative | $9.6M | $11.9M |
| Loss from operations | -$35.3M | -$60.1M |
| Interest income | $3.3M | $6.2M |
| Interest expense | -$1.9M | -$1.9M |
| Total other income, net | $1.4M | $4.3M |
| Net loss | -$33.8M | -$55.9M |
| Net loss per share - basic | -$0.56 | -$0.94 |
| Net loss per share - diluted | -$0.56 | -$0.94 |
| Weighted average common shares outstanding - basic | 60.1M shares | 59.5M shares |
| Weighted average common shares outstanding - diluted | 60.1M shares | 59.5M shares |
Every line of the balance sheet in the latest annual report, as filed.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $70.0M | $54.5M | |
| Marketable securities | $0 | $46.6M | |
| Prepaid expenses and other current assets | $1.7M | $2.9M | |
| Total current assets | $71.8M | $104.1M | |
| Deferred offering costs | $0 | $267.3K | |
| Right-of-use assets | $275.9K | $267.0K | |
| Total assets | $72.1M | $104.6M | |
| Accounts payable | $158.5K | $180.5K | |
| Accrued expenses | $6.1M | $12.1M | |
| Current portion of debt | $15.2M | $31.4K | |
| Operating lease liabilities | $280.5K | $271.6K | |
| Deferred collaboration revenue | $6.0M | $6.0M | |
| Total current liabilities | $27.8M | $18.6M | |
| Long-term debt, net of current portion | $0 | $15.0M | |
| Total liabilities | $27.8M | $33.6M | |
| Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding | $0 | $0 | |
| Common stock, voting, $0.001 par value; 150,000,000 authorized and 59,648,278 and 59,195,951 shares issued and outstanding, respectively | $60.2K | $59.6K | |
| Additional paid-in capital | $528.1M | $521.0M | |
| Accumulated other comprehensive income | $0 | $37.4K | |
| Accumulated deficit | -$484.0M | -$450.1M | |
| Total stockholders equity | $44.3M | $71.0M | $119.8M |
| Total liabilities and stockholders equity | $72.1M | $104.6M | |
| Preferred Stock, par value | $0.00 | $0.00 | |
| Preferred Stock, shares authorized | 15.0M shares | 15.0M shares | |
| Preferred Stock, shares issued | 0 shares | 0 shares | |
| Preferred Stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 150.0M shares | 150.0M shares | |
| Common stock, shares issued | 60.2M shares | 59.6M shares | |
| Common stock, shares outstanding | 60.2M shares | 59.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.9
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$33.8M | -$55.9M |
| Stock-based compensation | $6.1M | $8.0M |
| Non-cash interest expense | $218.3K | $177.3K |
| Net amortization of premium on marketable securities | -$1.1M | -$1.7M |
| Depreciation and amortization expense | $252.0K | $249.6K |
| Write-off of deferred offering costs | $267.3K | $0 |
| Prepaid expenses and other current assets | $1.2M | $2.1M |
| Accounts payable | -$22.0K | -$1.2M |
| Accrued expenses and other liabilities | -$6.3M | $5.0M |
| Net cash used in operating activities | -$33.3M | -$43.2M |
| Purchases of marketable securities | -$40.3M | -$96.9M |
| Maturities of marketable securities | $88.0M | $52.0M |
| Net cash provided by (used in) investing activities | $47.7M | -$44.9M |
| Issuance costs | $0 | -$267.3K |
| Proceeds from exercise of stock options | $1.1M | $350.3K |
| Proceeds from employee stock purchase plan | $19.6K | $38.1K |
| Debt end of term charge paid in cash | $0 | -$292.5K |
| Net cash provided by (used in) financing activities | $1.1M | -$171.4K |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | $15.5M | -$88.3M |
| Cash paid during the period for interest | $1.7M | $1.8M |
Former names
Recent filings
- Sep 29, 20268-K
- Aug 12, 2026SCHEDULE 13G
- Aug 6, 202610-Q
- Jul 30, 20268-K
- Jul 27, 2026SCHEDULE 13G/A
- Jul 15, 20268-K
- Jun 11, 20263
- Jun 11, 20264
- Jun 11, 20264
- Jun 11, 20264
- Jun 11, 20264
- Jun 11, 20264
- Jun 11, 20264
- Jun 11, 20264
- Jun 10, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceALDX quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11